The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down to one or two months, according to the agency. The federal outfit's "Commissioner's National Priority Voucher" (CNPV) program will include a "limited number of vouchers" for "companies aligned with U.S. national priorities," according to a June 17 press release.